Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia.

Compared with patients who did not receive allo‐HSCT, the CDCAG+VEN group showed a trend of increased OS at 1 year compared with the CDCAG group, albeit with non‐significant statistical differences between the groups (36.4% vs. 25.0%, p = 0.606, Figure S4B ). 3.4 Safety The most commonly observed treatment‐related toxicities of any grade were hematological adverse events (AE) reported in all patients.

also in 53,322 other papers